Skip to main content
eClinicalMedicine logoLink to eClinicalMedicine
. 2022 Jul 1;50:101532. doi: 10.1016/j.eclinm.2022.101532

Reliability of bedside tests for diagnosing peripheral arterial disease in patients prone to medial arterial calcification: A systematic review

Jeroen JWM Brouwers a,b,1,, Siem A Willems a,b,1, Lauren N Goncalves c, Jaap F Hamming a, Abbey Schepers a
PMCID: PMC9256539  PMID: 35812995

Summary

Background

Medial arterial calcification (MAC), frequently associated with diabetes mellitus (DM) and chronic kidney disease (CKD), is a systemic vascular disorder leading to stiffness and incompressible arteries. These changes impede the accuracy of bedside tests to diagnose peripheral arterial disease (PAD). This review aimed to evaluate the reliability of bedside tests for the detection of PAD in patients prone to MAC.

Methods

A systematic search (Pubmed, Embase, Web of Science, Cochrane, and Emcare) was performed according to the PRISMA guidelines to identify relevant studies providing data on the performance of bedside tests for the detection of PAD in patients prone to MAC. Studies were included when bedside test were compared to a reference standard. Primary endpoints were the positive and negative likelihood ratios (PLR, NLR). Methodological quality and risk of bias were evaluated using the QUADAS-2 tool.

Findings

In total, 23 studies were included in this review. The most commonly evaluated test was the ankle-brachial index (ABI), followed by toe-brachial index (TBI), toe pressure (TP) measurements, and continuous wave Doppler (CWD). The majority of patients were older, male, and had DM. We found that ABI <0·9 was helpful to diagnose PAD, but failed to rule out PAD (NLR >0·2). The same applied for TP (NLR >0·3) and TBI (5 out of 6 studies revealed an NLR >0·2). CWD (loss of triphasic pattern) is reliable to exclude PAD (NLR 0-0·09), but was only validated in two studies. Overall, methodological quality was poor which led to risk of bias in 20 studies.

Interpretation

The diagnosis of PAD in patients prone to MAC remains challenging. The ABI performed reasonably in the diagnosis of PAD, while the CWD (loss of triphasic signal) can be used to rule out PAD. This systematic review showed that test performances were generally poor with serious concerns in methodological quality of the included studies. We therefore counsel against the use of a single bedside test.

Funding

None to declare.

Keywords: Peripheral arterial disease, Diagnosis, Non-invasive diagnostics, Medial arterial calcification, Diabetes mellitus, Chronic kidney disease, Systematic review


Research in context.

Evidence before this study

Peripheral arterial disease (PAD) is an increasing problem worldwide and is intertwined throughout all medical care. Medial arterial calcification (MAC), common in diabetes mellitus and chronic kidney disease, decreases the accuracy of bedside tests leading to a challenge in daily clinical practice. Early identification of PAD is particularly needed in these patients, allowing for the prompt initiation of cardiovascular risk management (CVRM) and thus reduce the risk of events.

Added value of this study

This systematic review compiled 23 diagnostic studies regarding 5404 patients prone to MAC. Overall, no singular bedside test showed sufficient ability to diagnose and rule out PAD in this patient group. The ankle-brachial index (<0.9 and exclusion of >1.3) seemed useful to diagnose PAD, while the continuous wave Doppler (loss of triphasic signal) provided reliable performance to rule out PAD.

Implications of all the available evidence

Both for ruling in and ruling out PAD, the performance of current bedside tests was disappointing. Generally, risk of bias was high in the included studies with respect to patient selection and interpretation of the bedside tests. These results should strengthen guideline recommendations to renounce the use of a singular bedside test for patients prone to MAC.

Alt-text: Unlabelled box

Introduction

Peripheral arterial disease (PAD) of the lower extremity is considered a clinical manifestation of systemic atherosclerosis. It is estimated that more than 200 million people are suffering from PAD worldwide.1 Non-invasive bedside tests such as the ankle-brachial index (ABI) are considered accurate for the diagnosis of PAD. However, the accuracy of bedside testing can be affected by medial arterial calcification (MAC), leading to falsely elevated and unreliable results.2, 3, 4, 5, 6

MAC is a complex and poorly understood pathological process resulting in incompressible arteries due to calcification of the media of the arterial wall. The increase in arterial wall stiffness impedes bedside diagnostic tools reliant on hemodynamic changes to detect PAD.7,8 This process is thought to be characteristic of aging, and is expedited in the presence of diabetes mellitus (DM) and chronic kidney disease (CKD).9, 10, 11 Research suggests that MAC is present in approximately one third of patients with DM, and up to 70% in amputations for critical limb ischemia.12, 13, 14 MAC has been shown to be an independent predictor of cardiovascular mortality, while another study found that patients with DM and PAD have an impaired quality of life and an increased risk of adverse cardiac and limb events.15,16

While the accurate diagnosis of PAD in patients with MAC can be challenging, timely recognition of critical limb ischemia and initiation of treatment in this patient population is pertinent to reduce delayed wound healing, prevent (major) lower limb amputation, and mortality in diabetic patients with PAD.17,18 It is expected that the number of patients with DM will increase to nearly 370 million people by 2030 worldwide.19 Therefore, reliable non-invasive bedside tests to diagnose PAD in patients prone to MAC is of the utmost importance. Recently two systematic reviews were published regarding bedside tests in patients with DM.20,21 However, bedside diagnostics should be tested in a wider context. MAC causes incompressible arteries and is the underlying problem of the poor performance of the bedside tests. Thus, bedside tests must not only be investigated in patients with DM, but in all patients prone to MAC such as patients with CKD and an ABI >1.3. A complete overview of the diagnostic performance of bedside tests in patients prone to MAC is lacking. Therefore, the aim of this systematic review is to evaluate the reliability of bedside tests compared to reference imaging techniques for diagnosing PAD in patients prone to MAC.

Methods

Search strategy

This study was conducted according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines22 and was not registered in a registry. A literature search was performed in PubMed, Embase (OVID-version), Web of Science, Cochrane Library, and Emcare until February 2021. The search string and justification of the strategy can be found in Supplement S1. Two reviewers (JB, SW) independently screened the titles and abstracts for eligibility of inclusion. Disagreements were resolved in a discussion meeting between two reviewers (JB, SW). Full text articles of the selected abstracts were assessed for inclusion, and the data was extracted.

Selection criteria

We aimed to evaluate the reliability of bedside tests compared to reference tests to diagnose PAD. Bedside tests were considered as any non-invasive technique to detect PAD at the point-of-care. These tests should also be readily available and easy in use. To be eligible for inclusion, studies were required to comply with the following criteria: I) evaluated a bedside (e.g. ABI, TBI, toe pressure, oximetry, pulsations, Doppler waveform) index test compared to a reference test; II) All included patients in the (sub)analyses had to be prone to MAC, defined as DM, CKD or ABI >1·3; III) published in English.

Although digital subtraction angiography (DSA) is regarded as the gold standard for the diagnosis of PAD, it is invasive and carries risks. Magnetic resonance angiography (MRA),23 computed tomography angiography (CTA),24 and duplex ultrasonography (DUS)25 have all been proven to accurately diagnose PAD, and were thus included as reference tests as well. The primary outcomes of interest regarding diagnostic accuracy were the positive likelihood ratio (PLR) and negative likelihood ratio (NLR), because these outcomes reflect the test's ability to rule in or rule out disease (PAD). The interpretation of these likelihood ratios is shown in Table 1. Furthermore, sensitivity and specificity of the index tests were also mentioned. We excluded articles that compared bedside tests to each other, reported insufficient data about PLR, NLR, sensitivity, and specificity, investigated serum markers, or were case reports.

Table 1.

The interpretation of likelihood ratios and their effect on post-test probability of disease.51

Positive likelihood ratio (PLR) Negative likelihood ratio (NLR) Interpretation: effect on ability to rule in/rule out disease
>10 <0·1 Large
5-10 0·1-0·2 Moderate
2-5 0·2-0·5 Small
1 1 No change

Data extraction and quality assessment

Data extraction was performed and verified independently by two investigators (JB, SW). For all articles, extracted data consisted of relevant patient characteristics, the index test performed, correlated imaging modalities, and the diagnostic value (PLR, NLR, sensitivity and specificity) of the index test compared to a reference standard. Measures of test performance such as PLR, NLR, sensitivity, and specificity were extracted and calculated (if necessary) from the accessible data.

Methodological quality and risk of bias were assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool, specifically designed for diagnostic accuracy studies.26 Due to heterogeneity in patient selection, clinical diversity, and the threshold values of index- and reference tests, a meta-analysis could not be performed.

Role of the funding source

There is no direct or indirect funding to declare. Authors JB and SW had access to the data and took the decision to submit for publication.

Results

Overview of studies

An overview of the article selection for this systematic review is reported according to the PRISMA 2020 guidelines (Figure 1).22 A total of 1017 articles were found, of which 23 studies were eventually included, comprising of 6869 patients. Thirteen of the 23 selected studies included solely patients prone to MAC, described as DM, CKD, or incompressible arteries (n=4038). A sub-analysis specifically assessing test performance in patients prone to MAC was performed in the other ten studies (n=1366). Of the studies selected, 12 were prospective cohort or cross-sectional studies (n=3847), nine were retrospective studies (n=2837), and two were prospective case-control studies (n=185). In the 23 included studies, the number of study participants ranged from 1627 to 2188,28 and the ages of subjects at baseline ranged from 53 to 77 years old. The diagnosis of DM was specifically noted in 3693 patients. Duration of DM was mentioned in 12 studies,28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 and ranged from 2 to 24 years. Eleven of the included studies described the application of multiple bedside tests per patient population, while twelve studies explored the diagnostic value of a singular bedside test, as shown in Table 2. The ABI was the most commonly evaluated bedside test, mentioned in 18 of the 23 included studies. Table 2 describes the 13 other diagnostic parameters discussed in this review. Seventeen studies used DUS as the reference standard for confirming the presence of PAD, and mostly defined >50% stenosis as cut-off value (12 studies). Alternative reference tests included MRA in three studies, CTA in one study, and DSA in two studies.

Figure 1.

Figure 1

Flow diagram illustrating article selection process according to the PRISMA guidelines.22

Table 2.

Evidence table of all included studies.

Author & year (ref) Country Study design & setting Population (n, age, gender, comorbidity, patient characteristics) Index/non-invasive/point of care test Reference test; definition of PAD Index test performance (sensitivity/specificity/PLR/NLR) Comments/opinion
AbuRahma et al.40
2020
United States of America Single-center retrospective cohort study Overall
N = 1162 patients with
symptomatic PAD
Mean age: 65·4 years
Gender: not specified
57% of patients had claudication symptoms
43% of patients had limb threatening ischemia
Subgroup analysis
Diabetes (46%: 535 patients)
CKD (16%: 186 patients)
Age/gender: not specified
ABI <0.9
TBI <0·7
DUS (PAD was defined as >50% stenosis) Current results only include the subgroup analysis.
ABI:
Diabetics
Sens: 51 (46·1-56·3)
Spec: 89 (84·3-92·5)
PLR: 4·64
NLR: 0·55
TBI:
Diabetics
Sens: 84 (76·0-90·3)
Spec: 58 (46·1-69·9)
PLR: 2·0
NLR: 0·28


CKD
Sens: 43 (34·3-52·7)
Spec: 95 (88·7-98·4)
PLR: 8·6
NLR: 0·6

CKD
Sens: 77 (61·4-88·2)
Spec: 64 (42·5-82·0)
PLR: 2·14
NLR: 0·36
The proportion of patients who had TBI is unclear.
The proportion of patients who had a reference test is unclear in the specific subgroups.
*Aubert et al.29
2014
France Single-centercross-sectional cohort study N = 200 patients with diabetes (400 lower limbs)
Mean age: 65 years
Gender: 80% male
Mean duration of DM was 13 years
ABI ≤0·90 or ≥1·30
Foot pulses missing or weak
DUS (PAD was defined as >70% stenosis) ABI:
Sens: 42·3%
Spec: 80%
PLR: 2·11
NLR: 0·72
Foot pulses missing or weak:
Sens: 69·2%
Spec: 71·9%
PLR: 2·46
NLR: 0·43
Patients with CKD (eGFR < 30 ml/min) were excluded.
Buschmann et al.41
2018
Austria Single-centerprospective cohort study Overall
N = 166 patients suspected of PAD
Mean age: 70 years
Gender: 76% male
Subgroup analysis
Diabetes (76 patients)
Mean age: 70 years
Gender: 68% male
Hypertension: 89%
CVD: 82%
CKD: 25%
ABI ≤0·88
ACCmax <4·4 m/sec2
Relative Pulse Slope Index (RPSI) 58·00s−1
DSA (PAD was defined as >50% stenosis) Current results only include the subgroup analysis.
ABI:
Sens: 56%
Spec: 83%
PLR: 3·29
NLR: 0·53
ACCmax:
Sens: 57%
Spec: 98%
PLR: 28·5
NLR: 0·44


RPSI:
Sens: 57%
Spec: 95%
PLR: 11·4
NLR: 0·45
Only patients with ABI of ≤0·90 or ≥1·30 and >25% stenosis at DUS were referred for DSA. The proportion is unclear.
Patients who were diagnosed with atherosclerotic stenosis of >25% but who did not have a DSA available were excluded. The proportion is unclear.
Clairotte et al.42
2009
France Single-centerprospective cohort study Overall
N = 146 consecutive patients (292 lower limbs), referred to the physiology department for Doppler ultrasound evaluation of PAD
Mean age: 62 years
Gender: 68% male
Subgroup analysis
Diabetes (83 patients)
Mean age: 63 years
Gender: 61% male
Doppler and oscillometric derived ABI <0·90 DUS (PAD was defined as systolic velocity ratio >2·0) Current results only include the subgroup analysis.

Doppler ABI:
Sens: 54%
Spec: 97%
PLR: 17
NLR: 0·47

Oscillometric ABI:
Sens: 29%
Spec: 96%
PLR: 7·9
NLR: 0·74
Unblinded study
The NLR was recalculated by the present research group since the NLR results in the original paper were incorrect.
Faglia Ezio et al.30
2010
Italy Single-centerprospective cohort study N = 261 patients with diabetes and rest pain and/or foot ulcer in 1 limb
Mean age: 73 years
Gender: 67% male
Mean duration of DM was 18 years
Ankle pressure (AP) <70 mm Hg
Transcutaneous oxygen tension (TcPO2) <50 mm Hg
DSA (PAD was defined as >50% stenosis) AP:
Sensitivity: 33%
Spec: N/A
PLR: N/A
NLR: N/A

TcPO2 ≤30 mmHg:
Sensitivity: 82%
Spec: N/A
PLR: N/A
NLR: N/A

TcPO2 ≤50 mmHg:
Sensitivity: 100%
Spec: N/A
PLR: N/A
NLR: N/A
Unblinded study
Only patients with AP <70 mm Hg and/or TcPO2 <50 mm Hg underwent DSA.
All included patients had >50% stenosis on DSA probably due to the selection of patients.
As a result, it was not possible to calculate specificity.
AP not measurable in 42% patients (13% arterial calcifications).
Homza et al.31
2019
Czech Republic Single-centerprospective cohort study N = 62 patients with diabetes (124 limbs)
Mean age: 68 years
Gender: 74% male
Mean duration of DM was 8 years
Doppler ABI using highest ankle pressure (hABI) <0·9 or >1·4
Doppler ABI using lowest ankle pressure (lABI) <0·9 or >1·4
Oscillometric ABI <0·9 or >1·4
DUS (PAD was defined as >50% stenosis) Higher ABI:
Sens: 67%
Spec: 75%
PLR: 2·68
NLR: 0·44

Oscillometric ABI:
Sens: 61%
Spec: 94%
PLR: 10·17
NLR: 0·41
Lower ABI:
Sens: 87%
Spec: 76%
PLR: 3·63
NLR: 0·17
Patients with critical limb ischemia were excluded (Rutherford 4-6).
Hur et al.32
2018
South Korea Single-centerretrospective cohort study N = 324 patients with diabetes
Mean age: 63 years
Gender: 59% male
Mean duration of DM was 11 years
ABI <0·9 DUS (PAD was defined as >50% stenosis) ABI:
Sens: 17%
Spec: 99%
PLR: 17
NLR: 0·84
Patients with ABI >1·40 were excluded.
Janssen et al.33
2005
Germany Single-centerprospective cohortstudy N = 106 patients with diabetes who were hospitalized
Mean age: 72 years
Gender: 68% male
Mean duration of DM was 20 years
ABI <0·9
Ankle-Brachial Pressure (ABP) <70 mmHg
Pulsatility index (PI) <1·2
The need for revascularization on the basis of
a) clinical findings and
b) arteriographic findings.
ABI:
Sens: 71%
Spec: 42%
PLR: 1·22
NLR: 0·69

ABP:
Sens: 30%
Spec: 89%
PLR: 2·73
NLR: 0·79
PI:
Sens: 87%
Spec: 62%
PLR: 2·29
NLR: 0·21
In total, 54% of patients had medial arterial calcification (assessment on X-ray).
Li et al.28
2015
China Single-centercross-sectional cohort study Overall
N = 2188 patients with diabetes
Mean age: 61 years
Gender: 54% male

Subgroup analysis:
ABI > 1·3 (175 patients)
Mean age: 63 years
Gender: 59% male
Mean duration of DM was 9 years
ABI >1·45 DUS and MRA
438 underwent DUS/MRA due to abnormal ABI:
- 314 patients had DUS
- 124 patients had MRA
Current results only include the subgroup analysis.

ABI ≥1·45:
Sens: 65%
Spec: 85%
PLR: 4·33
NLR: 0·41
The optimal ABI threshold was calculated (determined with Youden index).
Threshold of reference test to diagnose PAD was unclear.
*Normahani et al.39
2020
United Kingdom Multicenter prospective cohort study N = 305 patients with diabetes (recruited from diabetic foot clinics)
Mean age: 72 years
Gender: 68% male
Mean duration of DM was 17 years
CKD was present in 17% of patients
Pulse palpation (absence of dorsalis pedis or posterior tibial artery pulse)
Audible Doppler (monophasic or absent signal in either vessel)
Visual Doppler with
handheld Doppler device (monophasic or absent signal in either vessel)
ABI < 0.9
TBI < 0.75
TcPO2 <40 mmHg
PAD-scan (the presence of an occlusion, venous like slow flow, monophasic waveform or a biphasic waveform with adverse features in either vessel)
DUS (PAD was defined as >50% stenosis) ABI
Sens: 60%
Spec: 75%
PLR: 2.46
NLR: 0.53

Audible Doppler
Sens: 74%
Spec: 76%
PLR: 3.04
NLR: 0.35

Visual Doppler
Sens: 83%
Spec: 75%
PLR: 3.28
NLR: 0.23

Pulse palpation
Sens: 43%
Spec: 81%
PLR: 2.22
NLR: 0.71
TBI
Sens: 60%
Spec: 86%
PLR: 4.26
NLR: 0.47

TcPO2
Sens: 31%
Spec: 79%
PLR: 1.43
NLR: 0.88


PAD-scan
Sens: 95%
Spec: 77%
PLR: 4.06
NLR: 0.07
PAD-scan was performed using a portable ultrasound machine with a linear 6-14Hz transducer. A ‘normal’ biphasic waveform indicated no PAD. However, several adverse features are mentioned in this study leading biphasic waveforms to abnormal:
- Spectral broadening
- Infilling of the spectral window
- Long diastolic forward flow - Slow systolic rise time
Perriss et al.43
2005
Denmark Single-centerretrospective cohort study N = 104 patients with end-stage renal failure who underwent CE-MRA of the lower extremity
Mean age: 53 years
Gender: 71% male
80 asymptomatic patients
24 symptomatic patients (16 claudication, 5 ulcers, 3 other symptoms)

Study population consisted of 69 patients (had both ABI and MRA)
ABI <0·90 CE-MRA (PAD was defined as >50% stenosis) ABI in asymptomatic patients (n=48):
Sens: 56·3%
Spec: 87·5%
PLR: 4·50
NLR: 0·50

ABI in combined patients (n=69):
Sens: 74·3%
Spec: 85·3%
PLR: 5·05
NLR: 0·30
ABI in symptomatic patients (n=21):
Sens: 89·5%
Spec: 50%
PLR: 1·79
NLR: 0·21
In 80 out of 104 patients, the indication for MRA was pretransplant evaluation (asymptomatic).
19 of 80 asymptomatic patients had incompressible vessels (24%).
Premalatha et al.34
2002
India Single-centerprospective cohort study
N = 100 hospital admitted patients with diabetes and severe foot infections

Mean age: 60 years
Gender: not specified

Mean duration of DM was 12 years
ABI <0·90 DUS (PAD was defined as >50% stenosis) ABI:
Sens: 70·6%
Spec: 88·5%
PLR: 6·14
NLR: 0·33
Six patients with calcification of peripheral vessels were excluded (unclear how presence of calcification was assessed).
Ro et al.44
2013
South Korea Single-centerretrospective cohort study N = 97 patients (194 legs), who had coincidentally undergone CTA, PPG, ABI and CWD for the evaluation of PAD
Mean age: 67 years
Gender: 91% male
Subgroup analysis
Diabetes (44 patients, 88 legs)
Mean age/gender: not specified
ABI <0.90
Continuous-Wave Doppler (CWD), considered positive if:
(1) Loss of triphasic pattern, or
(2) Decreased amplitude of more than 50% compared with the contralateral side, or
(3) Loss of reverse flow component.
Photoplethysmography (PPG) wave form, considered positive if:
(1) Loss of dicrotic
Notch, or
(2) Decreased amplitude of more than 50% compared
with contralateral side, or (3) rounding of peaks compared with
contralateral side.
CTA (PAD was defined as >50% stenosis) Current results only include the subgroup analysis.
ABI:
Sens: 74·7(64-83)
Spec: 88.9(57-98)
PLR: 6·73
NLR: 0·28

PPG:
Sens: 78·5 (68-86)
Spec: 89% (57-98)
PLR: 7·14
NLR: 0·24


CWD:
Sens: 97·5 (91-99)
Spec: 66·7 (35-88)
PLR: 2·93
NLR: 0·04
Saunders et al.27
2019
United Kingdom Single-centerretrospective cohort study
N = 16 patients (32 limbs)
Mean age: 66 years
Gender: 94% male
Selection criteria included confirmed incompressible vessels (defined as persistent flow with blood pressure
cuff inflated to >220 mm Hg) and MRA within the preceding 6 months with no interval arterial intervention. All patients had tissue loss
Vascular early warning system (VEWS) device MRA (PAD was defined as >50% stenosis) VEWS ≤0·94:
Sens: 73%
Spec: 80%
PLR: 3·65
NLR: 0·34
VEWS functions by using red and infrared optical sensors placed on the toe and dorsum of the foot to
register changes in blood volume within the microvasculature
that occur during a gravity-induced
functional test.
Sonter et al.47
2017
Australia Single-centerprospective cohort study
Overall
N = 90 patients (PAD analysis)
Mean age: 73 years
Gender: 58% male
Subgroup analysis
Diabetes (50 patients)
Mean age/gender: not specified
TBI <0·70
Toe pressure <70 mmHg
DUS (PAD was defined as >50% stenosis) Current results only include the subgroup analysis.
TBI:
Sens: 73·9%
Spec: 66·7%
PLR: 2·22
NLR: 0·39
Toe pressure:
Sens: 45·8%
Spec: 100%
PLR: infinite
NLR: 0·54
32% of patients had medial arterial calcification. However, it was unclear how presence of medial arterial calcification was assessed.
It was unclear if TBP <70 was pre-specified.
Tehan et al.45
2016
Australia Single-center prospective cross- sectional case-control study
Overall
N = 117 patients (PAD analysis)
Mean age: 73 years
Gender: 63% male
Subgroup analysis
Diabetes (72 patients)
Mean age: 72 years
Gender: 65% male
ABI ≤ 0·90 or > 1·4
TBI ≤ 0·70
Continuous-Wave Doppler (CWD), considered positive if monophasic pattern in either the dorsalis pedis or posterior tibial arteries,
demonstrated by low-resistance, slow systolic acceleration and no
diastolic flow reversal
DUS (PAD was defined as >50% stenosis) Current results only include the subgroup analysis.
ABI:
Sens: 45·2%
Spec: 92·7%
PLR: 6·17
NLR: 0·59
TBI:
Sens: 63·6%
Spec: 82·1%
PLR: 3·55
NLR: 0·44


CWD:
Sens: 74·2%
Spec: 92·9%
PLR: 10·39
NLR: 0·28
Ten percent of patients with diabetes had incompressible ankle pressures.
Tehan et al.48
2017
Australia Single-centerretrospective case-control study
Overall
N = 394 participants (suspected PAD)
Mean age: 77 years
Gender: 61% male
Subgroup analysis
Diabetes (176 patients)
Mean age: 75 years
Gender: 65% male
Toe pressure < 97 mmHg DUS (PAD was defined as >50% stenosis) Current results only include the subgroup analysis.
Toe pressure:
Sens: 73·7%
Spec: 72·4%
PLR: 2·67
NLR: 0·36
TP cutoff value was calculated based on ROC curves.
27% of patients had calcification of peripheral vessels visualised on DUS. However, it was unclear how presence of calcification was assessed.
Tehan et al.46
2018
Australia Single-centerretrospective case-control study
Overall
N = 160 patients (278 limbs) with suspected PAD

Mean age: 73 years
Gender: 69% male

Subgroup analysis
Diabetes (107 patients)
Mean age: 71 years
Gender: 73% male
ABI ≤ 0·9
Post-exercise ABI:
- Post exercise
ABI ≤ 0·9
- >20% reduction
compared to resting ABI
- >30mmHg reduction compared to Resting systolic ankle pressure
DUS (PAD was defined as >50% stenosis) Current results only include the subgroup analysis.


ABI:
Sens: 53·8%
Spec: 92·9%
PLR: 7·53
NLR: 0·50
Post-exercise ABI
(≤ 0·9):
Sens: 69·6%
Spec: 80·0%
PLR: 3·48
NLR: 0·38

Post-exercise
(≥20%) reduction
compared to resting ABI:
Sens: 59·6%
Spec: 61·1%
PLR: 1·53
NLR: 0·66
Post-exercise
(≥30mmHg) reduction in systolic ankle pressure:
Sens: 51·1%
Spec: 25·0%
PLR: 0·68
NLR: 1·96
28% of patients had incompressible ankle pressures.
31% of patients with diabetes had MAC visualised on CDUS.
MAC was determined based on DUS, but it is unclear which criteria were used.
The PLR/NLR for the post-exercise
(>30mmHg) reduction in systolic ankle pressure were recalculated by the present research group since the PLR/NLR results in the original paper were incorrect.
Tehan et al.49
2018
Australia Single-center retrospective case-control study
Overall
N = 396 patients (suspected PAD)
Mean age: 77 years
Gender: 61%

Subgroup analysis
Diabetes (176 patients)
Mean age: 75 years
Gender: 65% male
Subgroup analysis
Medial arterial calcification (98 patients)
Mean age/gender: not specified
Continuous wave Doppler (CWD): monophasic or absent signal. DUS (PAD was defined as >50% stenosis) Current results only include the subgroup analyses.
CWD (subgroup DM):
Sens: 82·8%
Spec: 88·3%
PLR: 7·09
NLR: 0·19

CWD (subgroup MAC):
Sens: 82·9%
Spec: 81·8%
PLR: 4·56
NLR: 0·21
Unblinded study
MAC was present in 25% of the patients with diabetes.
Subgroup analysis of MAC included both patients with and without diabetes.

MAC was determined based on DUS, but it is unclear which criteria were used.
Biphasic signals were considered as multiphasic (normal).
Ugwu et al.35
2021
Nigeria Single-center cross-sectional cohort study N = 163 patients with diabetes (319 legs) with clinical suspicion of lower extremity PAD
Mean age: 56 years
Gender: 47% male
Mean duration of DM was 8·6 years
ABI < 0·9 DUS (PAD was defined as >50%)
The severity of stenosis was
graded as follows:
(1) 50–75% =
mild stenosis
(2) 76–99% = moderate stenosis
(3) complete occlusion =
severe stenosis
ABI (overall):
Sens: 78·46%
Spec: 91%
PLR: 8·72
NLR: 0·24
ABI (moderate stenosis):
Sens: 93%
Spec: 91%
PLR: 10·33
NLR: 0·08
ABI (mild stenosis):
Sens: 54%
Spec: 91%
PLR: 6
NLR: 0·51
ABI (severe stenosis):
Sens: 100%
Spec: 91%
PLR: 11·11
NLR: 0
Seven patients with ABI >1·3 were excluded.
Unclear if study was prospective or retrospective.
*Vriens et al.36
2018
United Kingdom Single-center prospective cohort study
N = 60 patients with diabetes-related foot ulceration
Mean age: 66 years
Gender: 75% male

Mean duration of DM was 2 years
Comorbidity: - 38% CKD
Palpation of pulses
ABI <0·9 or >1·3
Ankle pressure: <70 mmHg

Toe pressure: <50 mmHg
TBI: <= 0·75
TcPO2: < 60mmHg
Pole test (the height - in cm - at which the
Doppler signal was lost while elevating the leg)
Waveform analysis by DUS (monophasic and/or damped waveforms)
DUS (PAD was defined as >50% stenosis) Palpation/pulses:
Sens: 55%
Spec: 60%
PLR: 1·38
NLR: 0·75
Ankle pressure:
Sens: 47%
Spec: 79%
PLR: 2·25
NLR: 0·67
TBI:
Sens: 89%
Spec: 45%
PLR: 1·62
NLR: 0·24
Pole test:
Sens: 28%
Spec: 97%
PLR: 10·29
NLR: 0·74
ABI:
Sens: 68%
Spec: 59%
PLR: 1·69
NLR: 0·53
Toe pressure:
Sens: 45%
Spec: 97%
PLR: 17·55
NLR: 0·56
TcPO2:
Sens: 28%
Spec: 66%
PLR: 0·81
NLR: 1·10
Waveform:
Sens: 85%
Spec: 100%
PLR: infinite
NLR: 0·15
Waveform analysis was not blinded to the reference test.
Williams et al.37
2005
United Kingdom Single-center prospective case-control study Overall
N = 68 individuals (130 limbs) with diabetes were screened for PAD (without critical ischemia)
Mean age/gender: not specified
Subgroup analysis
Diabetes (89 patients)
Mean age: 63-69 years
Gender: 74% male
Mean duration of DM was 11-24 years
Foot pulse: absence of one or both foot pulses.
ABI < 0·9

TBI <0·75
Continuous wave Doppler (CWD): loss of triphasic signal.
DUS (PAD was defined as significant velocity change and flow disturbance locally that resulted in loss of reverse flow distally, caused by occlusions or stenosis) Current results only include the subgroup analyses.
Diabetic no neuropathy (n=32 limbs)

Foot pulse:
Sens: 87%
Spec: 53%
PLR: 1·85
NLR: 0·25
TBI:
Sens: 91%
Spec: 65%
PLR: 2·6
NLR: 7·2
Diabetic neuropathy (n=57 limbs)
Foot pulse:
Sens: 81%
Spec: 56%
PLR: 1·84
NLR: 0·34
TBI:
Sens: 100%
Spec: 61%
PLR: 2·56
NLR: 0





ABI:
Sens: 100%
Spec: 88%
PLR: 8·33
NLR: 0
CWD:
Sens: 100%
Spec: 92%
PLR: 12·5
NLR: 0
ABI:
Sens: 53%
Spec: 95%
PLR: 10·6
NLR: 0·49

CWD:
Sens: 94%
Spec: 66%
PLR: 2·76
NLR: 0·09
Active foot disease, rest pain, or signs suggestive of lower limb critical ischemia were excluded.
The definition of significant velocity change in DUS was not specified.
Zhang et al.38
2010
China Single-center retrospective case-control study N = 184 patients with diabetes were screened for PAD
Mean age: 63 years
Gender: 74% male
Mean duration of DM was 11·5 years
ABI < 0·9 DUS (Large plaque>10 mm2 with 100% increase in peak systolic
velocity)
ABI:
Sens: 93·75%
Spec: 88·16%
PLR: 7·92
NLR: 0·07
Patients who had one leg with low ABI and one leg with high ABI were excluded.

Studies of high methodological quality are marked with asterisks (*).

ABI = Ankle-Brachial Index, ABP = Ankle-Brachial Pressure, ACCmax = Maximal Systolic Acceleration, AP = Ankle Pressure, CKD = Chronic Kidney Disease, CTA = Computed Tomography Angiography, CWD = Continuous Wave Doppler, DM = Diabetes Mellitus, DSA = Digital Subtraction Angiography, DUS = Duplex Ultrasonography, MRA = Magnetic Resonance Angiography, PAD = Peripheral Arterial Disease, PI = Pulsatility index, PPG = Photoplethysmography, RPSI = Relative Pulse Slope Index, TBI = Toe-Brachial Index, TcPO2 = Transcutaneous Oxygen Tension, and TP = Toe Pressure.

Quality assessment of included studies

The results of the quality assessment are illustrated in Table 3. Only three29,36,39 of the included studies were of high methodological quality (i.e. low risk of bias in all domains assessed). Risk of bias was generally high or unclear with respect to the selection of participants, and the conduct and interpretation of the index tests and reference standards. Applicability concerns were generally low with respect to the selection of patients, the index- and reference tests.

Table 3.

Methodological assessment of all included studies based on QUADAS-2 tool.

Author & year Risk of bias
Applicability concerns
Patient selection Index test Reference standard Flow & timing Patient selection Index test Reference standard
AbuRahma 202040 Unclear Low Unclear High Low Low Low
Aubert 201329 Low Low Low Low Low Low Low
Buschmann 201841 Low High Unclear High Low Low Low
Clairotte 200942 High High High Low Low Low Low
Faglia Ezio 201030 High Low High Low Low Low Low
Homza 201931 Low Low Unclear Low Low Low Low
Hur 201832 Low Low Unclear Low Unclear Low Low
Janssen 200533 High Low Unclear Low Low Low Unclear
Li 201528 High High Unclear High Unclear High Low
Normahani 202039 Low Low Low Low Low Low Low
Perriss 200543 High Unclear Unclear High High Low Low
Premalatha 200234 High Low Unclear High Low Low Low
Ro 201344 High Unclear Unclear Low Low Low Low
Saunders 201927 High Unclear Unclear Low Low Low Low
Sonter 201747 Low Unclear Unclear Low Low Low Low
Tehan 201645 Low Low Unclear Low Low Low Low
Tehan 201748 High High Unclear Low Low Low Low
Tehan 201846 High Low Unclear Low Low Low Low
Tehan 201849 High Low High Low Low Low Low
Ugwu 202135 Low Low Unclear Low Low Low Low
Vriens 201836 Low Low Low Low Low Low Low
Williams 200537 High Low Unclear Low High Low Low
Zhang 201038 Low Unclear Unclear High High Low Low

H = High = if any of the signaling questions for a domain were answered with ‘no’, potential for bias existed and was graded as high.

L = Low = if all signaling questions for a domain were answered with ‘yes’, the risk of bias was judged as low.

U = Unclear = this category was only used if insufficient data was reported to permit a judgment.

Ankle-brachial index

Eighteen studies evaluated the ABI to diagnose PAD in patients prone to MAC.28,29,31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 In these studies, 10 different variables were investigated (Table 4 shows an overview). In studies including patients with an ABI >1·3, the PLR ranged between 1·22 and 17, and the NLR ranged between 0 and 0·69 for an ABI with a threshold of <0·90. When an ABI of <0·9 or >1·3 to 1·4 was defined as abnormal, the PLR and NLR ranges changed to 1·69–6·17 and 0·44–0·72, respectively.

Table 4.

An overview of the different ABI variables to diagnose PAD.

Index test with threshold ABI >1·3 included/excluded in study population Number of studies Number of patients PLR NLR Sensitivity Specificity
ABI < 0·932,35 Excluded 2 487 8·72-17 0·24-0·84 17%-78·46% 91%-99%
ABI < 0·933,34,37, 38, 39, 40,42, 43, 44,46 Included 10 1801 1·22-17 0-0·69 53%-100% 42%-95%
ABI <0·9 or >1·3-1·429,31,36,45 Included 4 394 1·69-6·17 0·44-0·72 42·3%-68% 59%-92·7%
ABI < 0·8841 Included 1 76 3·29 0·53 56% 83%
Oscillometric ABI < 0.942 Included 1 83 7·9 0·74 29% 96%
Oscillometric ABI <0·9 or >1·431 Included 1 62 10·17 0·41 61% 94%
Lower ABI <0·9 or >1·431 Included 1 62 3·63 0·17 87% 76%
ABI >1·45 (Only patient with ABI >1·3 were included)28 Included 1 175 4·33 0·41 65% 85%
Post-exercise ABI (≤0·9)46 Included 1 107 3·48 0·38 69·6% 80·0%
Post-exercise (>20%) reduction compared to resting ABI46 Included 1 107 1·53 0·66 59·6% 61·1%

Ankle pressure

Three studies mentioned an absolute ankle pressure of <70mmHg as the threshold for diagnosing PAD. In two of these studies, a PLR of 2·25–2·73 and an NLR of 0·67–0·79 were found to detect PAD.30,33,36 It was not possible to calculate the PLR/NLR as a result of the selection of patients in one study. All included patients had >50% stenosis on DSA, so only the sensitivity of 33% could be given in this study.30 A post-exercise reduction of >30mmHg in systolic ankle pressure showed a lower PLR of 0·68 to detect PAD.46

Toe-brachial index; toe pressure

Six studies investigated the TBI as an index test for PAD (with cut-off values of below 0·70 and 0·75).36,37,39,40,45,47 In these studies, PLRs ranged from 1·62 to 4·26. NLRs fluctuated between 0 and 0·47. In the three studies that evaluated toe pressure, different cut-off values were used.36,47,48 Vriens et al. used a pressure below 50 mmHg as indicator for PAD, leading to a PLR of 17·55 and an NLR of 0·56.36 Sonter et al. studied a pressure below 70 mmHg, with an infinite PLR and an NLR of 0·54.47 Tehan et al. used a pressure below 97 mmHg, resulting in a PLR of 2·67 and an NLR of 0·36.48

Palpable pulsations

Four studies explored the palpation of foot pulses as a bedside test.29,36,37,39 Since these studies described different criteria for the diagnosis of PAD, these articles will be described separately. Aubert et al. regarded missing or weak foot pulses as an indicator for PAD, leading to a PLR of 2·46 and NLR of 0·43.29 Vriens et al. used the absence of foot pulses as PAD criterion, resulting in a PLR of 1·38 and an NLR of 0·75.36 Williams et al. and Normahani et al. considered the absence of one or both foot pulses as diagnostic of PAD. This resulted in PLR/NLR of 1.84/0.31 and 2.22/0.71 respectively.37,39

Waveform analysis

Waveform analysis, measured at the dorsalis pedis- or posterior tibial artery, is described in six articles (two studies investigated two techniques).36,37,39,44,45,49 Visual waveform analysis was conducted using a Continuous Wave Doppler (CWD) device in five studies, a Duplex ultrasound scanning (DUS) device in two studies, and photoplethysmography in one study. Abnormal waveform was heterogeneously defined. Two studies by Tehan et al. and Normahani et al. described PAD as the presence of a monophasic or dampened waveform using CWD, with a PLR ranging from 3·28 to 10·39 and an NLR of 0·19 to 0·28.39,45,49 Vriens et al. described an infinite PLR and an NLR of 0·15 for the detection of PAD by DUS waveform analysis, defined as a monophasic or damped waveform. Note that waveform analysis was not blinded to the reference test in this study.36 Loss of a triphasic pattern is another parameter for defining PAD and was investigated in two studies using CWD. The PLR varied between 2·76 and 12·5 and the NLR between 0 and 0·09.37,44 The detection of PAD by photoplethysmography waveform assessment showed a PLR of 7·14 and NLR of 0·24.44 Normahani et al. investigated the PAD-scan (waveform analysis performed using DUS), this is explained in detail in Table 2. This technique showed a PLR of 4.06 and NLR of 0.07.39

Transcutaneous oxygen pressure

Three studies investigated the reliability of transcutaneous oxygen pressure (TcPO2).36,39 Vriens et al. regarded a pressure below 60 mmHg as PAD, resulting in a PLR of 0·81 and an NLR of 1·10.36 Normahani et al. used a pressure below 40 mmHg, which showed a PLR of 1.43 and NLR of 0.88.39 Faglia Ezio et al. studied pressures below 30 and 50 mmHg, with a sensitivity of 82% and 100% respectively. Since all patients in this study had PAD (probably due to patient selection), specificity, PLR and NLR could not be calculated.30

Other

Novel arterial Doppler flow parameters, the maximum systolic acceleration (ACCmax) and the relative pulse slope index (RPSI) were explored by Buschmann et al.41 The ACCmax, defined as “maximum slope of the velocity curve in the systolic phase” detected PAD with a PLR of 28·5 and NLR of 0·44 when adopting a cut-off value of <4·4m/sec2. Janssen et al. described a colour duplex ultrasonography parameter, pulsatility index (PI), as a PAD diagnostic test.33 PI is defined as “the ratio of the maximum vertical excursions of the Doppler”, and showed a PLR of 2·29 and NLR of 0·21 for a threshold of <1.2. A pole test, the height in centimeters at which the Doppler signal can no longer be detected while passively elevating the leg, is assessed in one article and showed a PLR 10·29 and NLR 0·74.36 Lastly, a study by Saunders et al. described a Vascular Early Warning System device (VEWS).27 The VEWS device functions by measuring changes in blood volume in the microvasculature of the foot, as detected by infrared optical sensors. This method showed a PLR of 3·65 and NLR 0·34 when a cut-off of ≤0·94 was selected to detect PAD.

Discussion

To the best of our knowledge, this is the first systematic review on bedside tests to diagnose PAD in patients prone to MAC. While MAC can hamper the performance of bedside tests to diagnose PAD, only 23 studies investigated the accuracy of bedside tests in patients prone to MAC. Most studies were performed in Western countries, and included predominantly older males with DM. The included studies often contained small study populations and had flaws in methodological quality, raising serious concerns about their reliability. Overall, the performances of the different bedside tests were generally disappointing and highly variable between studies.

Worldwide, the ABI is the most frequently used bedside test to diagnose PAD.50 In 18 studies that evaluated the ABI, 10 different ABI variables were investigated (Table 4) in which the ABI threshold or study population (ABI >1·3 included or excluded) differed. In most studies an ABI <0·90 was defined as abnormal, followed by four studies that considered an ABI of <0·90 and >1·3–1·4 as PAD. Two studies investigated an ABI threshold of 0·9 and excluded patients with an ABI >1·3,32,35 which is in line with current guidelines2,50 in which patients with an ABI >1·3–1·4 should undergo alternative tests. In these two studies,32,35 the ABI could accurately rule in PAD with a PLR of 8·72–17, but it failed to rule out PAD (NLR 0·24–0·84). The same pattern was seen in all 18 studies, where 16 studies showed an insufficient NLR >0·2 (small effect on ability to rule out PAD). Generally, including patients with ABI >1·3 resulted in a lower performance to diagnose PAD (PLR 1·22–17). Of note, only one study investigated the use of the lowest ankle pressure to calculate the ABI, which lead to an improved performance of the test (compared to the highest ankle pressure).31

Since digital arteries are less affected by MAC, the measurement of toe pressure may be more reliable in patients with DM or CKD. Six studies investigated the use of TBI to diagnose PAD, but none of these studies found a moderate or large effect on the ability to diagnose PAD (PLR > 5).36,37,40,45,47 A mixed performance was seen in the ability to rule out PAD, with NLRs of 0–0·47. However, only one small study (N=57 limbs)37 had a large effect on the probability to exclude disease and resulted in this outlier (NLR 0). The other five studies did not have an accurate diagnostic effect to rule out PAD (NLR <0·2).36,40,45,47 In the three studies evaluating absolute toe pressure, it was remarkable to note that each study used a different threshold.36,47,48 A pressure of <50 mmHg appeared to be very accurate in diagnosing PAD (PLR 17·55), but provided poor performance to rule out disease (NLR 0·56).36 Raising the cut-off values to 70 and 97 mmHg resulted in a better, however still insufficient, ability to exclude PAD (NLR 0·54 and 0·36).47,48

Palpation of arterial pulsations during physical examination forms another cornerstone of clinical practice. While palpation of arterial pulsations may appear to be an attractive bedside test due to the inexpensive and readily applicable nature, the data supporting this method show limited diagnostic utility.29,36,37,39 In these studies, different definitions were regarded as abnormal: I) missing or weak,29 II) absence of one or both foot pulses,37,39 and III) absent of pedal pulses.36 Either way, deviations in palpation of arterial pulsations showed a poor performance to diagnose PAD in patients prone to MAC (PLR 1·38–2·46).29,36,37 Moreover, one study made the distinction between the presence (dorsalis pedis artery or posterior tibial artery) and absence of pedal pulses. This study showed that the presence of a palpable pedal pulse was insufficient to exclude PAD (NLR 0·75).36

Various other index bedside tests were investigated in the studies included in this review. Visual waveform analysis performed by continuous waveform Doppler (CWD) device showed the best test performance to rule out PAD with a relatively small variation in NLR (0–0·28).37,39,44,45,49 It is important to note that in three of the five studies PAD could not be definitively excluded (NLR >0·2), while three studies demonstrated a moderate to proficient ability to diagnose PAD (PLR >5).37,45,49 However, the definition of an abnormal test was not consistent between these studies. In three studies, the presence of a monophasic or dampened waveform indicated PAD,39,45,49 while a loss of a triphasic pattern was described as abnormal in the other two studies.37,44 When a loss of a triphasic pattern was used with CWD, PAD could be accurately ruled out (NLR 0–0·09).37,44 Although very reliable, this cut-off would be hard to implement in daily clinical practice, since the majority of patients prone to MAC have dampened, monophasic, or biphasic waveforms. Therefore, the addition of a loss of triphasic pattern with CWD as criterium for PAD will be of diminished value in clinical practice. Notably, only one of the studies included in this review mentioned the use of audible waveform analysis, with limited performance (PLR 3.04 and NLR 0.35).39 The PAD-scan waveform assessment, as described by Normahani et al. seems promising and can accurately rule out PAD (NLR 0.07), however this bedside test is only investigated in one study and could be complex to intepretate.39 Furthermore, the evidence supporting the ankle pressure30,33,36 and TcPO230,36,39 as a bedside test in patients with suspected MAC was sparse and poor results were found.

For clinicians, diagnosing PAD in patients with DM or CKD presents a major clinical challenge. Due to comorbidities such as neuropathy, patients frequently have atypical or no symptoms such as ischemic rest pain.8 Also, clinical examination provides insufficient reliable information to determine which patients have PAD or need further investigations. Additionally, this review shows that current index tests lack the ability to reliably diagnose or rule out PAD. All these considerations stress the importance of the need for a better bedside test, chiefly since early revascularization in patients with critical limb ischemia is essential to decrease future complications, and minimize morbidity in this patient group.17,18 Moreover, early identification of diabetic patients with PAD is essential to promptly start cardiovascular risk management (CVRM) and thus reduce the risk of events.15 It is therefore crucial to have a test that can reliably rule out PAD (i.e. have a low NLR). In this way, the diagnosis is less likely to be missed and more patients will be referred for additional imaging, CVRM, and timely revascularization if necessary. Although this would be the most optimal scenario, it is contrary to currently used tests, in which a high PLR and suboptimal NLR is generally seen.

This systematic review has several limitations. First, the overall methodological quality of the included studies was low. Risk of bias or a concern regarding applicability was present in 20 of the 23 included studies. The QUADAS 2-tool showed a notably high risk of bias regarding patient selection. Additionally, sample sizes were small; in 10 of the included studies less than 100 patients were included. Secondly, the heterogeneity in results was high, with wide ranging PLR and NLR values. Thirdly, data presentation was not uniform across studies exploring a specific technique, and many studies showed a wide variation in index test thresholds. Finally, performing a meta-analysis of the data presented in this review was not possible due to both clinical and methodological heterogeneity. Clinical variation was present due to heterogeneous patient groups (DM versus CKD, infection, age), bedside tests (with corresponding cut-off values and way of measurement), reference test (method and percentage of stenosis defined as PAD) and different exclusion criteria across the studies. Methodological heterogeneity was also present, and included study design (prospective vs. retrospective) and risk of bias (blinding of study). We thus advise tentative interpretation of the results presented in this review, and emphasize the need for standardized research using the QUADAS 2-tool26 to establish clinical applicability. Also, future (prospective) studies should focus on ruling out PAD, with emphasis on a homogeneous patient group in which all patients receive the same reference test.

Overall, it remains challenging to rule in or rule out PAD in patients prone to MAC. Based on the results of this systematic review, we counsel against the use of a single bedside test. The ABI (<0·9 and exclusion of >1·3) seems useful to diagnose PAD, and CWD (loss of triphasic pattern) was accurate to rule out PAD. However, the included studies must be interpreted with caution due to serious concerns pertaining to the reliability of these studies and thereby the clinical applicability of the bedside tests explored. Not only more methodologically well-designed studies should be performed, but alternative bedside tests must also be investigated to improve the diagnostic accuracy in patients with MAC.

Contributors

Literature search: JB, SW, LG, JH, AS

Figure and tables: JB, SW, LG

Study design: JB, SW, LG, JH, AS

Data collection: JB, SW

Data analysis and interpretation: JB, SW, LG, JH, AS

Writing the manuscript: JB, SW, LG

Critical review of manuscript: JH, AS, LG

All authors take full responsibility for the content of the publication.

Data sharing statement

There is no primary data to share. The utilized search strategy can be found in the supplement and, if wanted, be used to reproduce the extracted articles in the corresponding databases.

Declaration of interests

We declare no competing interests.

Acknowledgements

We would like to thank and acknowledge Jan Schoones (JS) for his help regarding the search strategy. No funding to declare.

Footnotes

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2022.101532.

Appendix. Supplementary materials

mmc1.docx (104.2KB, docx)

References

  • 1.Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379–381. doi: 10.1016/j.atherosclerosis.2018.05.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Aboyans V, Ricco JB, Bartelink MEL, et al. Editor's choice - 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Eur J Vasc Endovasc Surg. 2018;55:305–368. doi: 10.1016/j.ejvs.2017.07.018. [DOI] [PubMed] [Google Scholar]
  • 3.Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia. 1993;36:615–621. doi: 10.1007/BF00404070. [DOI] [PubMed] [Google Scholar]
  • 4.Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20(suppl 1):S90–S95. doi: 10.1002/dmrr.464. [DOI] [PubMed] [Google Scholar]
  • 5.Sawka AM, Carter SA. Effect of temperature on digital systolic pressures in lower limb in arterial disease. Circulation. 1992;85:1097–1101. doi: 10.1161/01.cir.85.3.1097. [DOI] [PubMed] [Google Scholar]
  • 6.Van Tongeren RB, Bastiaansen AJ, Van Wissen RC, Le Cessie S, Hamming JF, Van Bockel JH. A comparison of the Doppler-derived maximal systolic acceleration versus the ankle-brachial pressure index or detecting and quantifying peripheral arterial occlusive disease in diabetic patients. J Cardiovasc Surg (Torino) 2010;51:391–398. [PubMed] [Google Scholar]
  • 7.Lanzer P, Hannan FM, Lanzer JD, et al. Medial arterial calcification: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78:1145–1165. doi: 10.1016/j.jacc.2021.06.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hinchliffe RJ, Forsythe RO, Apelqvist J, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update) Diabetes Metab Res Rev. 2020;36(suppl 1):e3276. doi: 10.1002/dmrr.3276. [DOI] [PubMed] [Google Scholar]
  • 9.Leskinen Y, Salenius JP, Lehtimäki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40:472–479. doi: 10.1053/ajkd.2002.34885. [DOI] [PubMed] [Google Scholar]
  • 10.Liew YP, Bartholomew JR, Demirjian S, Michaels J, Schreiber MJ., Jr Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. Clin J Am Soc Nephrol. 2008;3:1084–1089. doi: 10.2215/CJN.04411007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu IT, Wu JS, Yang YC, Huang YH, Lu FH, Chang CJ. Mild chronic kidney disease associated with greater risk of arterial stiffness in elderly adults. J Am Geriatr Soc. 2013;61:1758–1762. doi: 10.1111/jgs.12445. [DOI] [PubMed] [Google Scholar]
  • 12.Ndip A, Jude EB. Emerging evidence for neuroischemic diabetic foot ulcers: model of care and how to adapt practice. Int J Low Extrem Wounds. 2009;8:82–94. doi: 10.1177/1534734609336948. [DOI] [PubMed] [Google Scholar]
  • 13.Nelson AJ, Raggi P, Wolf M, Gold AM, Chertow GM, Roe MT. Targeting vascular calcification in chronic kidney disease. JACC Basic Transl Sci. 2020;5:398–412. doi: 10.1016/j.jacbts.2020.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.O'Neill WC, Han KH, Schneider TM, Hennigar RA. Prevalence of nonatheromatous lesions in peripheral arterial disease. Arterioscler Thromb Vasc Biol. 2015;35:439–447. doi: 10.1161/ATVBAHA.114.304764. [DOI] [PubMed] [Google Scholar]
  • 15.Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509–1526. doi: 10.1161/CIRCRESAHA.116.303849. [DOI] [PubMed] [Google Scholar]
  • 16.Niskanen L, Siitonen O, Suhonen M, Uusitupa MI. Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care. 1994;17:1252–1256. doi: 10.2337/diacare.17.11.1252. [DOI] [PubMed] [Google Scholar]
  • 17.Prompers L, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51:747–755. doi: 10.1007/s00125-008-0940-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Vouillarmet J, Bourron O, Gaudric J, Lermusiaux P, Millon A, Hartemann A. Lower-extremity arterial revascularization: is there any evidence for diabetic foot ulcer-healing? Diabetes Metab. 2016;42:4–15. doi: 10.1016/j.diabet.2015.05.004. [DOI] [PubMed] [Google Scholar]
  • 19.Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047. [DOI] [PubMed] [Google Scholar]
  • 20.Forsythe RO, Apelqvist J, Boyko EJ, et al. Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: a systematic review. Diabetes Metab Res Rev. 2020;36(suppl 1):e3277. doi: 10.1002/dmrr.3277. [DOI] [PubMed] [Google Scholar]
  • 21.Normahani P, Mustafa C, Shalhoub J, et al. A systematic review and meta-analysis of the diagnostic accuracy of point-of-care tests used to establish the presence of peripheral arterial disease in people with diabetes. J Vasc Surg. 2021;73:1811–1820. doi: 10.1016/j.jvs.2020.11.030. [DOI] [PubMed] [Google Scholar]
  • 22.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Menke J, Larsen J. Meta-analysis: accuracy of contrast-enhanced magnetic resonance angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern Med. 2010;153:325–334. doi: 10.7326/0003-4819-153-5-201009070-00007. [DOI] [PubMed] [Google Scholar]
  • 24.Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJ. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA. 2009;301:415–424. doi: 10.1001/jama.301.4.415. [DOI] [PubMed] [Google Scholar]
  • 25.Eiberg JP, Gronvall Rasmussen JB, Hansen MA, Schroeder TV. Duplex ultrasound scanning of peripheral arterial disease of the lower limb. Eur J Vasc Endovasc Surg. 2010;40:507–512. doi: 10.1016/j.ejvs.2010.06.002. [DOI] [PubMed] [Google Scholar]
  • 26.Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–536. doi: 10.7326/0003-4819-155-8-201110180-00009. [DOI] [PubMed] [Google Scholar]
  • 27.Saunders DJ, Bleasdale L, Summerton L, Hancock A, Homer-Vanniasinkam S, Russell DA Assessment of the utility of a vascular early warning system device in the assessment of peripheral arterial disease in patients with diabetes and incompressible vessels. Ann Vasc Surg. 2019;58:160–165. doi: 10.1016/j.avsg.2018.11.033. [DOI] [PubMed] [Google Scholar]
  • 28.Li Q, Zeng H, Liu F, et al. High ankle-brachial index indicates cardiovascular and peripheral arterial disease in patients with type 2 diabetes. Angiology. 2015;66:918–924. doi: 10.1177/0003319715573657. [DOI] [PubMed] [Google Scholar]
  • 29.Aubert CE, Cluzel P, Kemel S, et al. Influence of peripheral vascular calcification on efficiency of screening tests for peripheral arterial occlusive disease in diabetes–a cross-sectional study. Diabet Med. 2014;31:192–199. doi: 10.1111/dme.12309. [DOI] [PubMed] [Google Scholar]
  • 30.Faglia E, Clerici G, Caminiti M, Quarantiello A, Curci V, Somalvico F. Evaluation of feasibility of ankle pressure and foot oximetry values for the detection of critical limb ischemia in diabetic patients. Vasc Endovascular Surg. 2010;44:184–189. doi: 10.1177/1538574409359430. [DOI] [PubMed] [Google Scholar]
  • 31.Homza M, Machaczka O, Porzer M, Kozak M, Plasek J, Sipula D. Comparison of different methods of ABI acquisition for detection of peripheral artery disease in diabetic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019;163:227–232. doi: 10.5507/bp.2018.046. [DOI] [PubMed] [Google Scholar]
  • 32.Hur KY, Jun JE, Choi YJ, et al. Color Doppler ultrasonography is a useful tool for diagnosis of peripheral artery disease in type 2 diabetes mellitus patients with ankle-brachial index 0.91 to 1.40. Diabetes Metab J. 2018;42:63–73. doi: 10.4093/dmj.2018.42.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Janssen A. Pulsatility index is better than ankle-brachial Doppler index for non-invasive detection of critical limb ischaemia in diabetes. Vasa. 2005;34:235–241. doi: 10.1024/0301-1526.34.4.235. [DOI] [PubMed] [Google Scholar]
  • 34.Premalatha G, Ravikumar R, Sanjay R, Deepa R, Mohan V. Comparison of colour duplex ultrasound and ankle-brachial pressure index measurements in peripheral vascular disease in type 2 diabetic patients with foot infections. J Assoc Physicians India. 2002;50:1240–1244. [PubMed] [Google Scholar]
  • 35.Ugwu E, Anyanwu A, Olamoyegun M. Ankle brachial index as a surrogate to vascular imaging in evaluation of peripheral artery disease in patients with type 2 diabetes. BMC Cardiovasc Disord. 2021;21:10. doi: 10.1186/s12872-020-01821-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Vriens B, D'Abate F, Ozdemir BA, et al. Clinical examination and non-invasive screening tests in the diagnosis of peripheral artery disease in people with diabetes-related foot ulceration. Diabet Med. 2018;35:895–902. doi: 10.1111/dme.13634. [DOI] [PubMed] [Google Scholar]
  • 37.Williams DT, Harding KG, Price P. An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. Diabetes Care. 2005;28:2206–2210. doi: 10.2337/diacare.28.9.2206. [DOI] [PubMed] [Google Scholar]
  • 38.Zhang H, Li XY, Si YJ, Lu XL, Luo XS, Liu ZY. Manifestation of lower extremity atherosclerosis in diabetic patients with high ankle-brachial index. Chin Med J (Engl) 2010;123:890–894. [PubMed] [Google Scholar]
  • 39.Normahani P, Poushpas S, Alaa M, et al. Diagnostic accuracy of point-of-care tests used to detect arterial disease in diabetes: TEsting for Arterial disease in Diabetes (TrEAD) study. Ann Surg. 2020 doi: 10.1097/SLA.0000000000004545. [DOI] [PubMed] [Google Scholar]
  • 40.AbuRahma AF, Adams E, AbuRahma J, et al. Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease. J Vasc Surg. 2020;71:937–945. doi: 10.1016/j.jvs.2019.05.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Buschmann EE, Li L, Brix M, et al. A novel computer-aided diagnostic approach for detecting peripheral arterial disease in patients with diabetes. PLoS One. 2018;13 doi: 10.1371/journal.pone.0199374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Clairotte C, Retout S, Potier L, Roussel R, Escoubet B. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients. Diabetes Care. 2009;32:1231–1236. doi: 10.2337/dc08-2230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Perriss R, Løkkegaard H, Løgager V, Chabanova E, Thomsen HS. Preliminary experience with contrast-enhanced MR angiography in patients with end-stage renal failure. Acad Radiol. 2005;12:652–657. doi: 10.1016/j.acra.2005.01.021. [DOI] [PubMed] [Google Scholar]
  • 44.Ro du H, Moon HJ, Kim JH, Lee KM, Kim SJ, Lee DY. Photoplethysmography and continuous-wave Doppler ultrasound as a complementary test to ankle-brachial index in detection of stenotic peripheral arterial disease. Angiology. 2013;64:314–320. doi: 10.1177/0003319712464814. [DOI] [PubMed] [Google Scholar]
  • 45.Tehan PE, Bray A, Chuter VH. Non-invasive vascular assessment in the foot with diabetes: sensitivity and specificity of the ankle brachial index, toe brachial index and continuous wave Doppler for detecting peripheral arterial disease. J Diabetes Complications. 2016;30:155–160. doi: 10.1016/j.jdiacomp.2015.07.019. [DOI] [PubMed] [Google Scholar]
  • 46.Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of the postexercise ankle-brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes. Vasc Med. 2018;23:116–125. doi: 10.1177/1358863X17751259. [DOI] [PubMed] [Google Scholar]
  • 47.Sonter J, Tehan P, Chuter V. Toe brachial index measured by automated device compared to duplex ultrasonography for detecting peripheral arterial disease in older people. Vascular. 2017;25:612–617. doi: 10.1177/1708538117705293. [DOI] [PubMed] [Google Scholar]
  • 48.Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of resting systolic toe pressure for diagnosis of peripheral arterial disease in people with and without diabetes: a cross-sectional retrospective case-control study. J Foot Ankle Res. 2017;10:58. doi: 10.1186/s13047-017-0236-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Tehan PE, Sebastian M, Barwick AL, Chuter VH. How sensitive and specific is continuous-wave Doppler for detecting peripheral arterial disease in people with and without diabetes? A cross-sectional study. Diab Vasc Dis Res. 2018;15:396–401. doi: 10.1177/1479164118782887. [DOI] [PubMed] [Google Scholar]
  • 50.Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S–125S. doi: 10.1016/j.jvs.2019.02.016. e40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Hayden SR, Brown MD. Likelihood ratio: a powerful tool for incorporating the results of a diagnostic test into clinical decisionmaking. Ann Emerg Med. 1999;33:575–580. doi: 10.1016/s0196-0644(99)70346-x. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

mmc1.docx (104.2KB, docx)

Articles from eClinicalMedicine are provided here courtesy of Elsevier

RESOURCES